China decided not to include Paxlovid, an effective COVID-19 drug, in its list of medicines covered by basic medical insurance schemes. The move would effectively block millions of poor people from accessing Paxlovid after the temporary insurance arrangement expires at the end of March 2023. The wealthy and the middle class in China will still manage to get the antiviral drug as they can pay without insurance.